Zai Lab director granted 22,371 ADS equity award

DIEKMAN JOHN D reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

DIEKMAN JOHN D reported acquisition or exercise transactions in this Form 4 filing.

Zai Lab Ltd director John D. Diekman received an equity award of 22,371 American Depositary Shares as a grant, with no cash paid per share. These are restricted shares that will vest in full on June 17, 2027, as long as he continues serving on the board through that date. Following this award, he directly holds a total of 122,140 American Depositary Shares in the company.

Insider Trade Summary

Grant/Award: 22,371 shares

Grant/Award 1 txn

Insider DIEKMAN JOHN D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	American Depositary Shares	22,371	$0.00	$0.00

Holdings After Transaction: American Depositary Shares — 122,140 shares (Direct)

Footnotes (2)

1. F1. Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
2. F2. Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date.

Key Figures

Equity grant size: 22,371 American Depositary Shares Grant price per share: $0.0000 per ADS Holdings after transaction: 122,140 American Depositary Shares +2 more

5 metrics

Equity grant size 22,371 American Depositary Shares Grant to director on June 17, 2026

Grant price per share $0.0000 per ADS Equity award, not open-market purchase

Holdings after transaction 122,140 American Depositary Shares Director’s direct ownership following grant

ADS to Ordinary Share ratio 1 ADS = 10 Ordinary Shares Reported unit for this Form 4

Vesting date June 17, 2027 Restricted shares vest in full on this date

Key Terms

American Depositary Shares, restricted shares, vest in full, grant, award, or other acquisition

4 terms

American Depositary Shares financial

"Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

restricted shares financial

"Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

vest in full financial

"restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service"

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Zai Lab (ZLAB) report for John D. Diekman?

Zai Lab reported that director John D. Diekman received a grant of 22,371 American Depositary Shares. The award was granted at no cash cost per share and represents restricted stock that will vest in the future subject to continued board service.

How many Zai Lab (ZLAB) shares did John D. Diekman hold after this Form 4 grant?

After the grant, John D. Diekman directly held 122,140 American Depositary Shares of Zai Lab. This total includes the newly granted 22,371 restricted shares, which vest later, and reflects his updated direct ownership position reported in the Form 4 filing.

When do John D. Diekman’s new Zai Lab (ZLAB) restricted shares vest?

The 22,371 restricted American Depositary Shares granted to John D. Diekman vest in full on June 17, 2027. Vesting is conditioned on his continued service as a member of Zai Lab’s board of directors through that vesting date, according to the filing footnote.

What type of transaction code was used in this Zai Lab (ZLAB) Form 4?

The transaction used code “A,” indicating a grant, award, or other acquisition of shares. This code reflects that the shares were received as an equity award, not bought in the open market, and the price per share in the filing is listed as zero.

What does each Zai Lab (ZLAB) American Depositary Share represent in this Form 4?

Each American Depositary Share represents ten Ordinary Shares of Zai Lab, and the ADSs and Ordinary Shares are fully fungible. The Form 4 reports all amounts in terms of ADSs, providing a consistent unit for the director’s equity award and holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DIEKMAN JOHN D

(Last) (First) (Middle)

C/O ZAI LAB LIMITED

314 MAIN STREET, 4TH FLOOR, SUITE 100

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zai Lab Ltd [ ZLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares(1)	06/17/2026		A		22,371(2)	A	$0	122,140	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.

2. Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date.

	/s/ Bruce Blefeld, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)